Literature DB >> 9707613

A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

C Rogers1, E R Edelman, D I Simon.   

Abstract

Leukocytes are recruited early and abundantly to experimentally injured vessels, in direct proportion to cell proliferation and intimal growth. Activated circulating leukocytes and Mac-1 (CD11b/CD18, alphaMbeta2) expression are markers of restenosis risk in patients undergoing angioplasty. As angioplastied vessels lack endothelium but have extensive fibrin(ogen) and platelet deposition, we hypothesized that Mac-1-dependent adhesion to fibrin(ogen) is an important determinant of leukocyte recruitment and function, which may in turn promote intimal growth. To study this hypothesis we administered M1/70, an anti-CD11b blocking mAb, to rabbits (1 mg/kg i.v.) immediately before, and every 48 hr for 3, 6, or 14 days after, iliac artery balloon denudation or deeper stent-induced injury. M1/70, which bound to isolated rabbit monocytes and dose-dependently inhibited Mac-1-mediated fibrinogen binding in vitro, reduced leukocyte recruitment more than 2-fold 3, 6, and 14 days after injury. Neointimal growth 14 days after injury was markedly attenuated by treatment with M1/70 (intimal area after balloon injury, 0.12 +/- 0.09 mm2, compared with 0.32 +/- 0.08 mm2 in vehicle-treated controls, P < 0.01, and 0.38 +/- 0.08 mm2 in IgG-treated controls, P < 0.005; intimal area after stent injury, 0. 56 +/- 0.16 mm2, compared with 0.84 +/- 0.13 mm2 in vehicle-treated controls, P < 0.05, and 0.90 +/- 0.15 mm2 in IgG-treated controls, P < 0.02). Mac-1 blockade reduces experimental neointimal thickening, suggesting that leukocyte recruitment to and infiltration of injured arteries may be a valid target for preventing intimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707613      PMCID: PMC21474          DOI: 10.1073/pnas.95.17.10134

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Endovascular stent design dictates experimental restenosis and thrombosis.

Authors:  C Rogers; E R Edelman
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

2.  Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies.

Authors:  S D Wright; P E Rao; W C Van Voorhis; L S Craigmyle; K Iida; M A Talle; E F Westberg; G Goldstein; S C Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

3.  Stimulation of nonlymphoid mesenchymal cell proliferation by a macrophage-derived growth factor.

Authors:  B M Martin; M A Gimbrone; E R Unanue; R S Cotran
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes.

Authors:  S Garbisa; M Ballin; D Daga-Gordini; G Fastelli; M Naturale; A Negro; G Semenzato; L A Liotta
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

5.  A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro.

Authors:  S J Leibovich; R Ross
Journal:  Am J Pathol       Date:  1976-09       Impact factor: 4.307

6.  Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells.

Authors:  K A Ault; T A Springer
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

7.  Human monocyte-derived growth factor(s) for mesenchymal cells: activation of secretion by endotoxin and concanavalin A.

Authors:  K C Glenn; R Ross
Journal:  Cell       Date:  1981-09       Impact factor: 41.582

Review 8.  A cascade model for restenosis. A special case of atherosclerosis progression.

Authors:  P Libby; D Schwartz; E Brogi; H Tanaka; S K Clinton
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

9.  Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts.

Authors:  S Molossi; M Elices; T Arrhenius; R Diaz; C Coulber; M Rabinovitch
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1.

Authors:  F Sanchez-Madrid; P Simon; S Thompson; T A Springer
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  48 in total

Review 1.  Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.

Authors:  M I Furman; A L Frelinger III; A D Michelson
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

2.  Getting stents to go with the flow.

Authors:  R Wayne Alexander
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

3.  A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18.

Authors:  Jun Y Park; M Amin Arnaout; Vineet Gupta
Journal:  J Biomol Screen       Date:  2007-04

4.  Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge.

Authors:  H Epstein; E Grad; M Golomb; N Koroukhov; E R Edelman; G Golomb; H D Danenberg
Journal:  Atherosclerosis       Date:  2007-12-11       Impact factor: 5.162

Review 5.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 6.  New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.

Authors:  Wendy Weston; Vineet Gupta; Rebecca Adkins; Roland Jurecic
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 7.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

Authors:  Teruo Inoue; Kevin Croce; Toshifumi Morooka; Masashi Sakuma; Koichi Node; Daniel I Simon
Journal:  JACC Cardiovasc Interv       Date:  2011-10       Impact factor: 11.195

8.  A Genetic Model of Constitutively Active Integrin CD11b/CD18.

Authors:  Laisel Martinez; Xiaobo Li; Gioser Ramos-Echazabal; Hafeez Faridi; Zachary M Zigmond; Nieves Santos Falcon; Diana R Hernandez; Serene A Shehadeh; Omaida C Velazquez; Vineet Gupta; Roberto I Vazquez-Padron
Journal:  J Immunol       Date:  2020-09-16       Impact factor: 5.422

9.  Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

Authors:  Mohd Hafeez Faridi; Mehmet M Altintas; Camilo Gomez; Juan Camilo Duque; Roberto I Vazquez-Padron; Vineet Gupta
Journal:  Biochim Biophys Acta       Date:  2013-02-26

Review 10.  Leukocyte integrins and their ligand interactions.

Authors:  Young-Min Hyun; Craig T Lefort; Minsoo Kim
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.